Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea

•Survival outcomes in platinum-sensitive recurrent ovarian clear cell carcinoma were investigated by treatment.•The use of bevacizumab (BEV) was associated with improvements in progression-free survival (PFS) and overall survival (OS).•An association between optimal secondary cytoreductive surgery and improved PFS and OS was observed.•BEV might increase PFS and OS in patients who did not receive secondary cytoreductive surgery.